Aptose Biosciences Inc. Annual report pursuant to Section 13 and 15(d)

Note 13 - Collaborative Agreements (Details Textual) - USD ($) $ in Millions			12 Months Ended
	Dec. 14, 2021	Nov. 04, 2021	Dec. 31, 2021	Jun. 13, 2018	Mar. 07, 2018
Stock Issued During Period, Value, Licensing Fee			$ 7.5
CrystalGenomics [Member]
Collaborative Agreement, Milestone Payment			16.0
Collaborative Agreement, Regulatory Milestone			$ 44.0
Ohm Oncology [Member]
Collaborative Agreements, Potential Additional Milestone Payments Receivable					$ 125.0
HM43239 [Member]
License Fee, Total		$ 12.5
Payments for License Fee		5.0
Stock Issued During Period, Value, Licensing Fee	$ 7.5	$ 7.5
Stock Issued During Period, Shares, Licensing Fees (in shares)	3,235,548	3,235,548
Clinical Development and Global Regulatory Milestone, First Indication		$ 64.5
Clinical Development and Global Regulatory Milestone, Second Indication		34.0
Clinical Development and Global Regulatory Milestone, Third Indication		29.0
Global Sales Milestone		$ 280.0
Exclusive License to CG806 in China, Development Milestones [Member] \| CrystalGenomics [Member]
Collaborative Agreement, Regulatory Milestone				$ 6.0
Exclusive License to CG806 in China, Regulatory Milestones [Member] \| CrystalGenomics [Member]
Collaborative Agreement, Regulatory Milestone				$ 20.0